Advertisement

PRGO

Perrigo Company plc

Healthcare · USD

Set alert

Price alert · PRGO

All alert types
15.78 USD -0.12 -0.75%
As of Oct 30, 2026 Extended hours 15.78 0.00%
Bid
15.73 × 300
Ask
15.80 × 2,000
15.42 Day range 16.14
9.25 52-week range 20.74
YTD
+13.36%
1 year
-23.55%
Open
16.07
Prev close
15.90
Mkt cap
2.19B
Vol
3.35M
Avg vol
2.71M
EPS
-12.28
P/E
0.00
Div yield
7.30%
More statistics
Low
15.42
High
16.14
Forward P/E
6.61
Beta
0.69
Short ratio
8.12
Inst. own
115.75%
Dividend
1.16
Ex-div date
Aug 27, 2026
Earnings
Nov 4, 2026
50-d avg
14.78
200-d avg
12.44
1y target
16.50

MAX chart

Chart tools
Interval
PRGO all-time price chart5.0057.7110.4163.0215.7Jan 92Jan 99Dec 05Dec 12Nov 19Oct 26

Key statistics

Market cap
2.19B
Enterprise value
5.28B
Trailing P/E
0.00
Forward P/E
6.61
PEG ratio
1.14
Price / sales
0.53
Price / book
0.87
EPS (TTM)
-12.28
Beta
0.69
Dividend yield
7.30%
Payout ratio
1348.75%
Profit margin
-41.85%
Revenue (TTM)
4.14B
Revenue growth
-3.20%
Free cash flow
437.21M
Total cash
399.70M
Total debt
3.48B
Return on equity
-48.75%
Shares outstanding
138.77M
Short % of float
26.72%
50-day average
14.78
200-day average
12.44

Analyst view

Consensus: hold

Hold
Price target (mean) 16.50 +4.6% upside
Target (low)
14.00
Target (mean)
16.50
Target (high)
20.00
Ratings (0m) 5 1 buy · 4 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold4
  • Sell0
  • Strong sell0

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 0.51784.

Earnings history

Financials — quick view

All financials
PRGO Revenue — quarterly 1.02B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PRGO Net income — quarterly 74.50M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PRGO EPS — quarterly 0.54
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

PRGO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 27, 20260.511———
Aug 5, 2026Jun 27, 20260.3880.50+0.11+28.87%
May 6, 2026Mar 28, 20260.390.43+0.04+10.26%
Feb 26, 2026Dec 31, 20250.800.77-0.03-3.75%
Nov 5, 2025Sep 27, 20250.750.80+0.05+6.67%
Aug 6, 2025Jun 28, 20250.590.57-0.02-3.39%

Upgrades / downgrades

PRGO analyst upgrades and downgrades
DateFirmActionFromTo
Feb 27, 2026Canaccord GenuitymainBuyBuy
Dec 15, 2025JP MorganmainNeutralNeutral
Nov 6, 2025Canaccord GenuitymainBuyBuy
Nov 6, 2025JP MorgandownOverweightNeutral
Oct 27, 2025JefferiesmainHoldHold
Aug 7, 2025Canaccord GenuitymainBuyBuy

About Perrigo Company plc

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Ireland
Website
perrigo.com

News

Your note

Sign in to keep a note on PRGO — it syncs with the Stock Master app.

Insider holders

PRGO insider holders
InsiderRelationLatest transactionDateShares held
ALFORD BRADLEY ADirectorConversion of Exercise of derivative securitySep 10, 202646,121
ASHFORD ORLANDO DDirectorConversion of Exercise of derivative securityMay 13, 202627,717
BEZERRA EDUARDO GUARITAChief Financial OfficerConversion of Exercise of derivative securityJun 4, 202684,700
JANISH RONALD CRAIGChief Technology OfficerConversion of Exercise of derivative securityApr 3, 202535,558
KARABOUTIS ADRIANADirectorConversion of Exercise of derivative securityMay 13, 202527,629
LOCKWOOD-TAYLOR PATRICKFormerConversion of Exercise of derivative securityJun 4, 2026123,170

Institution ownership

PRGO institution ownership
Holder% heldSharesValueReported
Blackrock Inc.16.36%22,703,127358.03MJun 29, 2026
Neuberger Berman Group, LLC7.70%10,680,100168.43MJun 29, 2026
Vanguard Portfolio Management LLC6.52%9,045,661142.65MJun 29, 2026
Price (T.Rowe) Associates Inc6.27%8,700,421137.21MJun 29, 2026
State Street Corporation6.15%8,528,704134.50MJun 29, 2026
Fuller & Thaler Asset Management Inc.5.40%7,498,227118.25MJun 29, 2026

Fund ownership

PRGO fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%8,259,312130.25MSep 29, 2026
UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd.4.26%5,906,43693.14MJun 29, 2026
T. Rowe Price Mid-Cap Value Fund, Inc.3.27%4,541,19071.61MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%4,399,26169.38MJun 29, 2026
Invesco Exch-Trd Fd. TRT-Invesco High Yield Eqy. Dividend Achievers ET2.76%3,823,39760.29MAug 30, 2026
iShares Trust-iShares Russell 2000 ETF2.63%3,644,90957.48MSep 29, 2026
Advertisement